cMpl Inhibitors
2 drugsAbout cMpl
cMpl, or thrombopoietin receptor, is essential for platelet production and blood clotting. It regulates megakaryocyte development, proliferation, and differentiation. cMpl signaling pathways are crucial for maintaining adequate platelet levels.
cMpl is a therapeutic target for modulating platelet production. Currently, there is no genetic evidence directly linking cMpl to specific diseases, but its role in hematopoiesis makes it relevant to certain conditions.
Two FDA-approved small molecule drugs target cMpl: ELTROMBOPAG OLAMINE (Revolade) and Alvaiz. These drugs, developed by Zydus Pharms and Teva, respectively, are used in infectious disease.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Splenomegaly with only 1 trials.
Top cMpl Drugs
ZYDUS PHARMS and Teva are the only two companies with approved cMpl-targeting drugs.
The limited number of players suggests a concentrated market, but also an opportunity for new entrants.
cMpl Drug Modality Landscape
Modalities
Routes of Administration
cMpl is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore alternative modalities like antibodies or peptides to differentiate from existing therapies.
cMpl Clinical Trials 94 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 22 | 14 | 5 | 1 | 74% |
| Phase 2 | 50 | 35 | 7 | 8 | 83% |
| Phase 3 | 13 | 8 | 3 | 2 | 73% |
| Phase 4 | 9 | 5 | 1 | 3 | 83% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
cMpl Drug Approval Timeline (2023 - 2024)
The first cMpl-targeting drug was approved in 2023, with the most recent in 2024.
Recent approvals indicate continued interest in cMpl, but further market analysis is needed to assess saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 66 clinical trials targeting cMpl.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities